Ellis Martin Report: Entheon Biomedical (CNSX:ENBI) CEO Timothy Ko on the Ethical Clinical Use of DMT for Treating Substance Abuse, Depression, Anxiety and More

Join Ellis Martin for a conversation with Timothy Ko, the CEO of Entheon Biomedical (CNSX:ENBI) (OTCMKTS:ENTBF).

Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule. Entheon exists to invert the addiction-recovery ratio, turning the 'untreatable case' and 'lost cause' from the norm to the exception.

The company is committed to the legal development of regulated, safe & effective therapies, and in educating the public and medical profession as to the efficacy of psychedelic protocols when clinically administered in the optimum set and setting.

To view the Interview, please visit:
https://www.abnnewswire.net/press/en/104434/entheon

Entheon Biomedical Corp.
Joseph Cullen, Investor Relations
Telephone: +1 (778) 919-8615
Joe@entheonbiomedical.com
https://entheonbiomedical.com/